Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 2
2014 2
2015 1
2016 2
2017 6
2018 5
2019 3
2020 10
2021 5
2022 5
2023 6
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial.
McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, Perepu U, Anderson D, Gundabolu K, Kuzma C, Perez Botero J, Leon Ferre RA, Henkin S, Lenz CJ, Houghton DE, Vishnu P, Loprinzi CL. McBane RD 2nd, et al. Among authors: leon ferre ra. J Thromb Haemost. 2020 Feb;18(2):411-421. doi: 10.1111/jth.14662. Epub 2019 Nov 28. J Thromb Haemost. 2020. PMID: 31630479 Free article. Clinical Trial.
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.
Leon-Ferre RA, Jonas SF, Salgado R, Loi S, de Jong V, Carter JM, Nielsen TO, Leung S, Riaz N, Chia S, Jules-Clément G, Curigliano G, Criscitiello C, Cockenpot V, Lambertini M, Suman VJ, Linderholm B, Martens JWM, van Deurzen CHM, Timmermans AM, Shimoi T, Yazaki S, Yoshida M, Kim SB, Lee HJ, Dieci MV, Bataillon G, Vincent-Salomon A, André F, Kok M, Linn SC, Goetz MP, Michiels S; International Immuno-Oncology Biomarker Working Group. Leon-Ferre RA, et al. JAMA. 2024 Apr 2;331(13):1135-1144. doi: 10.1001/jama.2024.3056. JAMA. 2024. PMID: 38563834
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
O'Shaughnessy J, Brufsky A, Rugo HS, Tolaney SM, Punie K, Sardesai S, Hamilton E, Loirat D, Traina T, Leon-Ferre R, Hurvitz SA, Kalinsky K, Bardia A, Henry S, Mayer I, Zhu Y, Phan S, Cortés J. O'Shaughnessy J, et al. Among authors: leon ferre r. Breast Cancer Res Treat. 2022 Sep;195(2):127-139. doi: 10.1007/s10549-022-06602-7. Epub 2022 May 11. Breast Cancer Res Treat. 2022. PMID: 35545724 Free PMC article. Clinical Trial.
Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer.
Carter JM, Chumsri S, Hinerfeld DA, Ma Y, Wang X, Zahrieh D, Hillman DW, Tenner KS, Kachergus JM, Brauer HA, Warren SE, Henderson D, Shi J, Liu Y, Joensuu H, Lindman H, Leon-Ferre RA, Boughey JC, Liu MC, Ingle JN, Kalari KR, Couch FJ, Knutson KL, Goetz MP, Perez EA, Thompson EA. Carter JM, et al. Among authors: leon ferre ra. Nat Commun. 2023 Apr 18;14(1):2215. doi: 10.1038/s41467-023-37806-0. Nat Commun. 2023. PMID: 37072398 Free PMC article.
Fit for Chemo: Nerves May Thank You.
Leon-Ferre R, Ruddy KJ, Staff NP, Loprinzi CL. Leon-Ferre R, et al. J Natl Cancer Inst. 2016 Oct 28;109(2):djw208. doi: 10.1093/jnci/djw208. Print 2017 Feb. J Natl Cancer Inst. 2016. PMID: 27794125 No abstract available.
Roles of Notch Signaling in the Tumor Microenvironment.
D'Assoro AB, Leon-Ferre R, Braune EB, Lendahl U. D'Assoro AB, et al. Among authors: leon ferre r. Int J Mol Sci. 2022 Jun 2;23(11):6241. doi: 10.3390/ijms23116241. Int J Mol Sci. 2022. PMID: 35682918 Free PMC article. Review.
ASCO-Sponsored Oncology Student Interest Groups in the World.
Anampa-Guzmán A, Loli-Guevara S, Gutierrez-Narvaez CA, Nimboma LE, Leon-Ferre R. Anampa-Guzmán A, et al. Among authors: leon ferre r. JCO Glob Oncol. 2021 Sep;7:1586-1592. doi: 10.1200/GO.21.00353. JCO Glob Oncol. 2021. PMID: 34843374 Free PMC article. Review.
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial.
Haddad TC, Suman VJ, D'Assoro AB, Carter JM, Giridhar KV, McMenomy BP, Santo K, Mayer EL, Karuturi MS, Morikawa A, Marcom PK, Isaacs CJ, Oh SY, Clark AS, Mayer IA, Keyomarsi K, Hobday TJ, Peethambaram PP, O'Sullivan CC, Leon-Ferre RA, Liu MC, Ingle JN, Goetz MP. Haddad TC, et al. Among authors: leon ferre ra. JAMA Oncol. 2023 Jun 1;9(6):815-824. doi: 10.1001/jamaoncol.2022.7949. JAMA Oncol. 2023. PMID: 36892847 Free PMC article. Clinical Trial.
45 results